Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsOn September 5 2016,Bio-thera reached a strategic cooperation agreement with world class CRO, Quintiles. Under agreement with Bio-Thera, Quintileswith provide all-around international clinicalstudy and filingcooperative supportfor new drugs developed...
Great news! On May 18, Bio-Thera's recombinant humanized anti-VEGF monoclonal antibody injection(BAT1706) was approved for clinical trials by the China Food and Drug Administration (CFDA), marking our second approval for biosimilar clinical trialsthi...
On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706 (a bevacizumab biosimilar), which is currently carrying out its global development plan, has enrolled its first two healthy su...
